SHR A2102
Alternative Names: SHR-A2102Latest Information Update: 26 Jul 2024
At a glance
- Originator Shanghai Hengrui Pharmaceutical
- Class Antibodies; Antineoplastics; Drug conjugates; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; NECTIN4 protein modulators; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Oesophageal cancer
- Phase I Solid tumours
Most Recent Events
- 22 Jul 2024 Shanghai Hengrui Pharmaceutical plans a phase I/II trial for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Combination therapy, In adults, In the elderly) in China (NCT06512051)
- 30 Jun 2024 Shanghai Hengrui Pharmaceutical plans a phase I/II trial for Oesophageal cancer (Late-stage disease, Metastatic disease) in China (IV, Infusion) (NCT06474468)
- 20 Jun 2024 Phase-I/II clinical trials in Oesophageal cancer(Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in China (IV) (NCT06474468)